At 12.0% CAGR, the Europe Aortic Valve Replacement Devices Market is Projected to be Worth US$ 4,476.02 million by 2030, says The Business Market Insights

According to the Business Market Insights’ research, the Europe aortic valve replacement devices market was valued at US$ 1,812.09 million in 2022 and is expected to reach US$ 4,476.02 million by 2030, registering a CAGR of 12.0% from 2022 to 2030. Rising number of aortic valve replacement surgeries and increasing demand for minimally invasive techniques are among the critical factors attributed to the Europe aortic valve replacement devices market expansion.                     

The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.

A few technological advancements by the players in the aortic valve replacement devices are mentioned below:

•          In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.

•          In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.

•          In August 2021, CORCYM enrolled the first patient in the mitral, aortic, and tricuspid post-market study in a real-world setting, i.e., MANTRA. The first implantation was performed at Citta di Lecce Hospital in Italy with a Bicarbon aortic mechanical valve.

•          In September 2020, Boston Scientific Corporation introduced the ACURATE neo2 aortic valve system in Europe. This next-generation TAVI technology—a new platform designed with multiple features to improve the clinical performance of the original ACURATE neo platform—had an expanded indication for patients with aortic stenosis compared to the aortic valve system of the previous generation.

Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.

On the contrary, product recalls hurdle the growth of Europe aortic valve replacement devices market.

Based on product, the Europe aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve segment held 63.1% share of Europe aortic valve replacement devices market in 2022, amassing US$ 1,143.18 million. It is projected to garner US$ 2,916.92 million by 2030 to expand at 12.4% CAGR during 2022–2030.

Based on surgery, the Europe aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held 83.6% share of Europe aortic valve replacement devices in 2022, amassing US$ 1,514.20 million. It is projected to garner US$ 3,876.62 million by 2030 to expand at 12.5% CAGR during 2022–2030.  

Based on end user, the Europe aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held 64.2% share of Europe aortic valve replacement devices market in 2022, amassing US$ 1,163.73 million. It is projected to garner US$ 2,969.13 million by 2030 to expand at 12.4% CAGR during 2022–2030.

Based on country, the Europe aortic valve replacement devices market has been categorized into Germany, France, Italy, the UK, Spain, and the Rest of Europe.  Our regional analysis states that Germany captured 29.9% share of Europe aortic valve replacement devices market in 2022. It was assessed at US$ 540.91 million in 2022 and is likely to hit US$ 1,416.66 million by 2030, exhibiting a CAGR of 12.8% during 2022–2030.      

Key players operating in the Europe aortic valve replacement devices market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Artivion Inc, JenaValve Technology Inc, and Venus MedTech HangZhou Inc, among others.   

• In May 2023, Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low structural valve deterioration (SVD) rates in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, representing the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented at the 103rd annual meeting of the American Association for Thoracic Surgery.    
• In Feb 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com